Avanir Pharmaceuticals, Inc. (AVNR) Friday said the U.S. Food and Drug Administration or FDA has raised questions regarding the human factor validation study data, filed as part a of the company's New Drug Application or NDA for AVP-825, which is indicated for the treatment of Migraine. The FDA's preliminary written feedback to its NDA for AVP-825 was provided via a discipline review letter. Also, the FDA said the NDA review is not complete and that they may have additional comments regarding the application.
AVP-825 is a drug-device combination product consisting of low-dose sumatriptan powder, delivered intranasally utilizing a novel breath powered delivery technology.
Human factor testing focuses on the interactions between people and devices and its aim is to evaluate use-related risks and confirm that users can use the device safely and effectively.
The company said that approval of AVP-825 is unlikely to happen by the PDUFA date of November, 26, 2014.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.